Accelerated progression of IDH mutant glioma after first recurrence

BACKGROUND: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct subtype, reflected in the World Health Organization (WHO) 2016 revised diagnostic criteria. To inform IDH-targeting trial design, we sought to characterize outcomes exclusively within IDH mutant gliomas. METHODS: We retrospecti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Miller, Julie J, Loebel, Franziska, Juratli, Tareq A, Tummala, Shilpa S, Williams, Erik A, Batchelor, Tracy T, Arrillaga-Romany, Isabel, Cahill, Daniel P
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6502499/
https://ncbi.nlm.nih.gov/pubmed/30668823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz016
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars